Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Stock Overview
Explore Apellis Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.8B
P/E Ratio
62.25
EPS (TTM)
$0.36
ROE
0.19%
APLS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Apellis Pharmaceuticals, Inc. (APLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 47.90, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.53.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 62.25 and a market capitalization of 2.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.